



Brand Institute is proud to have partnered with 850 healthcare companies on over 3,100 names, including (22) twenty-two COVID-19 products and product candidates to date!

The first vaccine approved for the prevention of coronavirus disease 2019 (COVID-19)

COMIRNATY®



tozinameran



Pfizer and BioNTech's COVID-19 vaccine has a brand name: COMIRNATY®. The name was first announced by the Swiss regulatory authority, Swissmedic, and was included in the conditional marketing authorisation published by the European Medicines Agency (EMA). The approval of the brand name by other global regulatory agencies will follow their respective guidelines, policies and procedures.

Testing Apparatus/Diagnostic

ID NOW™ COVID-19

Rapid infectious disease detection and diagnosis



Abbott's molecular diagnostic platform that can test for the coronavirus (COVID-19) RdRp Gene and deliver positive results in as little as 5 minutes.

Vaccines

VAXZEVRIA

AstraZeneca's VAXZEVRIA is a vaccine preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older.

SPIKEVAX

The COVID-19 vaccine from Moderna works by strengthening the body's ability to defend itself against infection with (COVID-19).

Antiviral Therapeutics



Gilead's VEKLURY is an antiviral medication approved for post-infection treatment of COVID-19.

remdesivir

Gilead's Remdesivir is an antiviral medication approved for post-infection treatment of COVID-19.

galidesivir

BioCryst Pharmaceuticals' antiviral drug, Galidesivir, is being studied in Brazil as a potential treatment for COVID-19.

Compassionate Use Approvals



RedHill Biopharma received approval for compassionate use of opaganib for COVID-19 in Italy and Israel.

Repurposed Drugs



Heron Therapeutics' CINVANTI is being studied as a potential treatment for COVID-19.

Bemcentinib

BerGenBio's Bemcentinib in being studied as a potential treatment for COVID-19 in hospitalized patients.



Roche & Shionogi's Xofluza (baloxavir marboxil) is being studied in combination with favipiravir and lopinavir-ritonavir as a potential treatment in novel coronavirus pneumonia (COVID-19) patients.



Karyopharm Therapeutics' XPOVIO is being studied as a potential treatment for hospitalized patients with COVID-19



Sanofi's KEVZARA is being studied as a potential treatment for patients hospitalized with severe COVID-19 disease.



BeiGene's BRUKINSA is being studied in later-stage COVID-19 patients.



Alexion's ULTOMIRIS is being studied as a potential treatment for adult COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS).



Roche's ACTEMRA is being studied as a potential treatment for severely ill COVID-19 patients, who have been hospitalized with pneumonia.



Novartis, in alliance with Incyte, has announced plans to assess Jakavi/Jakafi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe COVID-19 pneumonia.



AstraZeneca to conduct a global clinical trial of Calquence (acalabrutinib) to treat cytokine storm that manifests in severely ill COVID-19 patients.



Novartis has plans to conduct a Phase III clinical trial to assess Ilaris (canakinumab) for the treatment of patients suffering from COVID-19 pneumonia.



EUSA Pharma is studying Sylvant (siltuximab) as a treatment for patients with the COVID-19 coronavirus who have developed serious respiratory complications.



Takeda Pharmaceuticals' Colcrys (colchicine) is being studied for potential efficacy against COVID-19 by Researchers at the Montreal Heart Institute and the University of Montreal.

BASEL +41-78-879-4619	BOSTON (781) 602-6044	CHICAGO (312) 475-9600	DALLAS (512) 369-9100	FRANKFURT +49-1726-574-189	LONDON +44-7896-875-113	LOS ANGELES (310) 830-6111	MIAMI (305) 984-6889	NEW YORK (212) 557-2100
OTTAWA (613) 482-1333	RALEIGH-DURHAM (919) 572-9311	ROCKVILLE (301) 984-1055	SAN FRANCISCO (415) 421-3200	SÃO PAULO +55 11 945-364083	SEATTLE (206) 204-5111	SEOUL 82(0) 8000-4842	TOKYO 81(80) 6688-6653	TORONTO (416) 622-5777